Targeted therapy effective for patients with advanced bladder cancer and specific gene mutations

An international Phase II clinical trial led by researchers at MD Anderson Cancer Center found that treatment with the FGFR inhibitor erdafitinib resulted in a 40% response rate for patients with metastatic bladder cancers marked by mutations in the FGFR3 gene.

Arlene Siefker-Radtke, M.D., principal investigator on the trial and professor of Genitourinary Medical Oncology at MD Anderson, discusses the importance of this clinical trial for patients with bladder and other urothelial cancers.

Request an appointment at MD Anderson by calling 1-877-632-6789 or online: https://my.mdanderson.org/RequestAppointment.